A Randomized, Open Label, 2-Period Crossover Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2009
At a glance
- Drugs PF 5212371; Tolbutamide
- Indications Osteoarthritis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Wyeth
- 11 Aug 2009 Actual end date changed from Jul 2006 to Aug 2006 as reported by ClinicalTrials.gov.
- 16 Mar 2007 New trial record.